Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Wall Street ends choppy session lower as tech shares drop
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
Amphastar Pharmaceuticals (AMPH) PT Lowered to $19 at Jefferies Following Strong 2Q
August 11, 2017 8:22 AM EDTJefferies lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $20.00) while maintaining a Buy rating following the company's 2Q. AMPH reported EPS of $0.11, exceeding estimates by $0.07 driven by a topline of ~$65M, which topped forecasts by $5.2M.
Management appears more... More
